anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND AND AIM: Hepatic fibrosis, one of the main reasons for death globally, is a serious complication of chronic liver disorders. However, the available therapies for liver fibrosis are limited, ineffective, and often associated with adverse events. Hence, seeking for a novel, effective therapy is warranted. Our objective was to investigate the potential efficacy of ferulic acid (FA), a phenolic phytochemical, at different doses in hindering the progress of concanavalin A (Con A)-induced hepatic fibrosis and explore the involved mechanisms.
METHODS: Thirty-six mice were assorted into 6 groups (n = 6): Group I (control); group II received FA (20 mg/kg/day orally for 4 weeks); group III received Con A (6 mg/kg/week/i.v.) for 4 weeks; groups IV, V, and VI received Con A and were offered FA at 5, 10, and 20 mg/kg/day, respectively.
RESULTS: The data showed the palliative effect of FA against Con A-induced fibrosis in a dose-dependent manner. This was obvious from the recovery of liver markers and hepatic architecture with the regression of fibrosis in FA-treated mice. FA abolished Con A-mediated oxidative insults and promoted the antioxidant enzyme activities, which run through the Nrf2/HO-1 signaling. Additionally, FA suppressed Con A-induced increase in NF-kB and IL-β levels, and TNF-α immune-expression. The anti-fibrotic effect of FA was evident from the drop in TGF-β, smad3 levels, α-SMA expression, and hydroxyproline content.
CONCLUSION: FA attenuated Con A-induced liver fibrosis through stimulating Nrf2 signaling, suppressing NF-kB, and inhibiting the TGF-β/smad3 signaling pathway. Thus FA can be considered as a promising therapy for combating liver fibrosis.
Few studies have investigated the impact of primary tumor resection (PTR) on patients with distant metastasis medullary thyroid carcinoma (DMMTC). This population-based study aims to assess the application of PTR in DMMTC patients, ascertain its benefits, and identify optimal surgical indications. DMMTC Patients diagnosed between 2010 and 2020 were included through the Surveillance, Epidemiology, and End Results (SEER) program. Logistic regression analysis identified driving factors of surgical decision-making. Propensity score matching (PSM), Kaplan-Meier method, and Cox regression were utilized to compare overall survival (OS) and disease-specific survival (DSS) between surgical and non-surgical groups. Subgroup analyses were performed to determine optimal surgical indications. Of 238 DMMTC patients included, 122 (51.3%) patients underwent PTR. Extrathyroidal extension and N1 stage emerged as independent factors promoting the surgical decision. PSM-adjusted survival analyses revealed significant advantages in both OS and DSS for the surgical group. Moreover, subgroup analyses indicated that except for patients aged ≥ 65 years, tumors ≤ 20 mm, or with multiple metastasized sites (> 1), the others significantly benefit from PTR. PTR significantly improves prognosis in selected DMMTC patients. The decision to undergo PTR in other patients should be based on a comprehensive assessment of the disease, surgeon's experience, and family discussions for potential survival benefits.
The invention relates to the technical field of medicine and pharmacy and discloses a dry suspension of cefpodoxime proxetil composition and a preparation method thereof. The dry suspension of cefpodoxime proxetil composition is made from the following raw materials in parts by weight: 50 of cefpodoxime proxetil, 60 of sucrose, 71 of hydroxypropyl methylcellulose, 71 of xanthan gum and 200 of 95% ethanol. The 95% ethanol can serve as a pharmaceutical humectant for preventing drugs from caking and increasing dissolubility of drugs. The stability and safety of traditional Chinese medicines in the dry suspension of cefpodoxime proxetil composition are substantially not changed, to achieve safety and efficacy of medication. The trials show that the dry suspension of cefpodoxime proxetil composition has strong antimicrobial effect and good stability. The dry suspension of cefpodoxime proxetil composition can be widely applied to treatment of upper/lower respiratory infections, skin and soft tissue infections, urogenital system infections and pediatric infections.
An overall complication rates for implant-based breast reconstruction (IBBR) have been reported from 29 to 46%, particularly in the setting of adjuvant radiotherapy. Although the majority of the literature describes autologous conversion in such scenario, a microsurgical flap is not always feasible. The aim of the paper is to assess surgical and patient-reported outcomes of breast reconstruction using a Latissimus Dorsi muscle Flap (LDMF), harvested without a back scar, in combination with a tissue expander for a two-staged reconstruction in the setting of a previously failed IBBR. All consecutive patients undergoing a two-stages LDMF IBBR between January 2016 and June 2020 were retrospectively identified. A minimal length vertical incision along the posterior axillary line was used for LD flap harvest. Demographic, clinical and surgical data were collected. Aesthetic outcome was evaluated with the Aesthetic Item Scale, and BREAST-Q was used to assess patients' reported outcomes. Twenty-one patients met the inclusion criteria. Mean age was 45.6 years, and the average follow-up was 41.2 months after tissue expander replacement with definitive implant. All patients completed the secondary reconstructive procedure, without major complications both at reconstructive and donor flap site. All women reported to be very satisfied with the final breast reconstruction. Second-attempt implant-based breast reconstruction for patients with a previously failed IBBR is challenging. A conversion from prosthetic to a mixed breast reconstruction with a "no-back scar" LD flap and tissue expander can be considered as a valuable strategy, especially when an abdominal-based autologous breast reconstruction is not feasible or refused by the patients.Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Rituximab 375 mg/m\^2 by vein (IV) over 3 to 8 hours weekly for 6 weeks in a row. ABVD Chemo: Adriamycin 25 mg/m\^2 IV, Bleomycin 10 U/m\^2 IV, Vinblastine 6 mg/m\^2 IV, DTIC 375 mg/m\^2 IV. Each but Rituximab over 3 hours every other week for a total of 12 treatments.
This study will evaluate, via a cluster-randomized controlled trial, the effectiveness of an innovative community-centered intervention that promotes thriving and resiliency to reduce community violence. In collaboration with community partners, this study will implement a Community Resiliency Collective Efficacy Intervention (CRCEI) to engage community members in dialogue on neighborhood transformation, racial and gender equity, community leadership, and organizing for social change. Facilitating discussion and community organizing within neighborhoods about child and youth thriving is expected to increase individual and neighborhood levels of collective efficacy and reduce community violence. Using a community-partnered participatory approach, this study will use a Community Thriving Matrix tool to engage youth and adult community members in ongoing dialogue on neighborhood transformation, community leadership, and organizing for social change. This focus on envisioning and creating neighborhoods in which children and adolescents can thrive is expected to translate to increased individual and neighborhood levels of collective efficacy as well as violence reduction. Comparison neighborhoods will receive health education sessions as a control intervention. The proposed study involves diverse neighborhoods in the Pittsburgh region and collecting survey data from youth (ages 13-19 years) and adult community participants (both male and female identified). Interviews with a sub-sample of community residents and facilitators and community site leads as well as observations of intervention delivery will provide qualitative information on processes of program implementation. This study will provide the first rigorous evaluation of this community-level prevention approach.
Healthy controls are matched to patients with PNES based on age (+ or - 1 year), gender, race and family income. They come to one laboratory visit to complete initial visit questionnaires and computer tasks.
Patients receive futibatinib PO QD on days 1-21 for cycles 1-9, and days 1-42 for subsequent cycles and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for cycles 1-9 and every 42 days for subsequent cycles for up to 2 years in the absence of disease progression or unacceptable toxicity.
User accounts can form any number of connections to any number of entities, enabling dynamic application functionality and data interaction regarding the user account and the connected entities. As a result, an individual can utilize the same user account and same application to access support from many entities. Entities may include social service organizations, groups of healthcare facilities, clinicians, medical devices, and other sources of support. The connection of a user account to an entity, updates the operations of the associated application system. For example, permissions regarding the transmission and modification of certain data associated with the user account and/or entity may be updated. Additionally, there may be additional functionality within software applications associated with the user account. There may be multiple possible forms of connections between a user account and a given entity, with each connection resulting in different outcomes. Connections can be removed and re-established as necessary.
A wound-healing preparation is composed of 50-90 wt. % of a sugar, 0.5-10 wt. % of povidone-iodine, and 1-20 wt. % of water. A buffer is also contained in an amount sufficient to adjust the pH of the preparation to 3.5-6. Preferably, the preparation may additionally contain 0.1-5 wt. % of an agent for imparting an appropriate consistency and stability, which is selected from polysaccharides and derivatives thereof.
The present invention relates, in general, to a kinase which in its activated state is capable of site-specific phosphorylation of IkappaBalpha, IkappaBalpha kinase. In particular, the present invention relates to the purified kinase, antibodies having binding affinity specifically to the kinase, and hybridomas containing the antibodies. This invention further relates to bioassays using protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with an undesired activation of NF-kappaB. This invention also relates to ligands, agonists, and antagonists of the kinase, and diagnostic and therapeutic uses thereof. This invention also relates to bioassays using the kinase to identify ligands, agonists, and antagonists. More specifically, this invention relates to selective inhibitors of the kinase.
The clinical importance of residual acoustic hearing in CI remains unclear. It is estimated that only five percent of adult candidates undergo CI. A major barrier is the loss of residual hearing associated with surgery, meaning most patients lose any or all residual hearing as a result of the CI surgery, especially since the majority of today's candidates do not suffer from complete deafness. Hence, many candidates are faced with the decision to relinquish their remaining acoustic hearing in exchange for electric hearing via the CI, as CI surgery often results in complete loss of any residual hearing. However, recent developments in hearing monitoring systems during CI surgery have shown promise for providing the surgeon with live feedback of how the cochlear implant insertion process is proceeding, allowing the surgeon to make intraoperative adjustments during the insertion, potentially minimizing any trauma caused by the insertion of the implant, ultimately helping preserve residual hearing. This ultimately could lead to improvements in the rates of hearing preservation. Therefore, the current study seeks to investigate: 1) the advantage of using a hearing monitoring system (electrocochleography) monitoring guided CI surgery on hearing preservation rates, 2) determine the benefit that hearing aid/cochlear implant combined hearing provides participants over non-hearing preservation CI (electric-only stimulation from the CI) on measures of speech perception and quality of life.
Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracyclines including ACTICLATE and ACTICLATE CAP. Clinical manifestations of IH include headache, blurred vision, diplopia, and vision loss; papilledema can be found on fundoscopy. Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline associated IH. Concomitant use of isotretinoin and ACTICLATE and ACTICLATE CAP should be avoided because isotretinoin is also known to cause pseudotumor cerebri.

Although IH typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. If visual disturbance occurs during treatment, prompt ophthalmologic evaluation is warranted. Since intracranial pressure can remain elevated for weeks after drug cessation patients should be monitored until they stabilize.
PROBLEM TO BE SOLVED: To provide a functional gel holding minute bubbles therein.SOLUTION: A prescribed high-pressure gas is sent into a bottom portion of an airtight container 1 from a compressed gas source 2 with a valve of a pipeline 3 opened, with a valve of another pipeline 5 closed and with a valve of an exhaust pipe 6 opened, so that the gas in a gas phase region in the upper part of the airtight container 1 is discharged and the gas phase region is filled with the prescribed gas. Next, the valve of the exhaust pipe 6 is closed, so that the pressure in the gas phase region is made higher. When the pressure in the gas phase region becomes higher, the solubility of the gas also becomes higher and a large amount of the gas is dissolved in water. After this, the valve of the pipeline 5 is opened and the high-pressure water in which the prescribed gas is dissolved up to the saturation solubility under high pressure is supplied to the water packed in another container 4 in advance. As a result, the pressure of the supplied high-pressure water is released in the water in the container 4 and the dissolved gas becomes minute bubbles. Then, a gelling agent is added into the container 4 so that the water (the low-viscosity solution) including minute bubbles is made gelatification.
PURPOSE: Understanding the complex bidirectional interactions between neurons and glioma cells could help to identify new therapeutic targets. Herein, the techniques and application of novel neuroscience tools implemented to study the complex interactions between brain and malignant gliomas, their results, and the potential therapeutic opportunities were reviewed.
METHODS: Literature search was performed on PubMed between 2001 and 2023 using the keywords "glioma", "glioblastoma", "circuit remodeling", "plasticity", "neuron networks" and "cortical networks". Studies including grade 2 to 4 gliomas, diffuse midline gliomas, and diffuse intrinsic pontine gliomas were considered.
RESULTS: Glioma cells are connected through tumour microtubes and form a highly connected network within which pacemaker cells drive tumorigenesis. Unconnected cells have increased invasion capabilities. Glioma cells are also synaptically integrated within neural circuitry. Neurons promote tumour growth via paracrine and direct electrochemical mechanisms, including glutamatergic AMPA-receptors. Increased glutamate release in the tumor microenvironment and loss of peritumoral GABAergic inhibitory interneurons result in network hyperexcitability and secondary epilepsy. Functional imaging, local field potentials and subcortical mapping, performed in awake patients, have defined patterns of malignant circuit remodeling. Glioma-induced remodeling is frequent in language and even motor cortical networks, depending on tumour biological parameters, and influences functional outcomes.
CONCLUSION: These data offer new insights into glioma tumorigenesis. Future work will be needed to understand how tumor intrinsic molecular drivers influence neuron-glioma interactions but also to integrate these results to design new therapeutic options for patients.
Adult patients with moderate to severe atopic dermatitis who are eligible for and will receive systemic therapy with abrocitinib by their treating dermatologist as part of standard healthcare (n=20). The choice of therapy is strictly done by the treating dermatologist only, and the reasons for the choice will be captured by a structured documentation.
MCI are defined by an actuarial neuropsychological method proposed by Jak and Bondi. Participants are considered to have MCI if any one of the following three criteria are met with a total Clinical Dementia Rating (CDR) score of 0.5 as well as failure to meet the criteria for dementia: (1) having impaired scores (defined as \>1 SD below the age-corrected normative mean) on both measures within at least one cognitive domain (i.e., memory, language, or speed/executive function); (2) having impaired scores in each of the three cognitive domains sampled; (3) the Functional Activities Questionnaire (FAQ) ≥9.
A system and method provide automatic image visualization of an object of interest. One or more data sets may include image data of the object of interest. The image data may include medical images and the object of interest may be an anatomical structure or region. One or more of the data sets may be analyzed to characterize the object. Subsequently, without requiring any user input, the image visualization may include automatically selecting a standard view at which to display the object of interest. For instance, based upon object classification, a predetermined orientation at which to display the object may be automatically selected. Additionally, to enhance the resolution of images displayed, the object of interest may be automatically resized or otherwise adapted based upon characteristics/settings of a display. For instance, the object of interest may be automatically resized to maximize the size of the object displayed within a window.
Single arm, multicenter, open-label study divided in two phases: 1. Induction phase; 2. Follow-up phase. Enrolled patients will start the induction phase and receive the courses of R-Lenalidomide. At the end of the third cycle of R-Lenalidomide (week 12 of the study), the patients will be evaluated for tumor response (complete assessment); the patients with Progressive Disease (PD) will be withdrawn of the study. Two weeks after the end last courses of R-Lenalidomide (week 26 of the study) patients will be evaluated for tumor response (complete assessment). Patients with Complete Response (CR) and Partial Response (PR), and with a stable disease will undergo the follow up phase, while patients with PD will be withdrawn of the study.
Participants received 200 mg/m\^2 paclitaxel (Taxol®) administered by intravenous infusion followed by carboplatin at AUC = 6 mg\*min/mL on Day 1 of a 21 day cycle. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent.
The local anesthetic solution mixture consists of dexamethasone 8 mg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 2 ml dexamethasone = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia.
The invention discloses pyrimidine derivatives represented by the formula (I), crystal forms, a preparation method and applications thereof. In the formula (I), the R1 represents a hydrogen atom, a halogen element atom, a C1-C6 alkyl group, a C1-C6 alkoxyl group, an amino group, or a substituted amino group, and the R2-R4 individually represent a hydrogen atom, an alkaline metal atom, and a C1-C6 alkyl group. SNNP of the provided compound 1 can be used as a drug carrier. The treatment effect of monomer nucleoside drugs and/or oligonucleotide drugs is prominently improved. The sustained-release effect is good. The treatment effect of drugs is enhanced. The drug using amount and medicine-taking frequency are both reduced. The bio-utilization degree of drugs is improved. The side and toxic effect of drugs are relieved. The drug carrier has a very good clinical application value. At the same time, the preparation method has the advantages of high yield, high product purity, low energy consumption, few steps, convenient operation, low cost, environment-friendliness, and safety, and is very suitable for industrial application.
Table 1 (Recommended Dosages) summarizes the recommended volumes and concentrations of lidocaine hydrochloride injection for various types of anesthetic procedures. The dosages suggested in this table are for normal healthy adults and refer to the use of epinephrine-free solutions. When larger volumes are required, only solutions containing epinephrine should be used except in those cases where vasopressor drugs may be contraindicated.

There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. Lidocaine hydrochloride injection is not approved for this use (see WARNINGS and DOSAGE AND ADMINISTRATION).

These recommended doses serve only as a guide to the amount of anesthetic required for most routine procedures. The actual volumes and concentrations to be used depend on a number of factors such as type and extent of surgical procedure, depth of anesthesia and degree of muscular relaxation required, duration of anesthesia required, and the physical condition of the patient. In all cases the lowest concentration and smallest dose that will produce the desired result should be given. Dosages should be reduced for children and for the elderly and debilitated patients and patients with cardiac and/or liver disease.

The onset of anesthesia, the duration of anesthesia and the degree of muscular relaxation are proportional to the volume and concentration (i.e., total dose) of local anesthetic used. Thus, an increase in volume and concentration of lidocaine hydrochloride injection will decrease the onset of anesthesia, prolong the duration of anesthesia, provide a greater degree of muscular relaxation and increase the segmental spread of anesthesia. However, increasing the volume and concentration of lidocaine hydrochloride injection may result in a more profound fall in blood pressure when used in epidural anesthesia. Although the incidence of side effects with lidocaine HCl is quite low, caution should be exercised when employing large volumes and concentrations, since the incidence of side effects is directly proportional to the total dose of local anesthetic agent injected.
PURPOSE:To provide a hair tonic containing a large amount of an oily component and having excellent hair tonic effect. CONSTITUTION:The objective hair tonic is prepared by using >=30wt.% (preferably about 50wt.%) of an oily component having hair tonic effect (e.g. rice embryo oil, squalane, jojoba oil and octyldodecyl oleate) and compounding various extracts having excellent hair tonic effect (e.g. natural vitamin), perfumery, water, etc. The present hair tonic contains a large amount of oily component which has been unable to use to the hair and, accordingly, the hair tonic component can be penetrated to the lesion in high efficiency and the unfavoralbe factors to the hair can also be eliminated. The hair tonic is applied to the scalp, irradiated with high-frequency electric wave and washed to remove the applied hair tonic.